首页 | 本学科首页   官方微博 | 高级检索  
     


Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label,randomised, phase 3 trial
Authors:Meletios A Dimopoulos  Hartmut Goldschmidt  Ruben Niesvizky  Douglas Joshua  Wee-Joo Chng  Albert Oriol  Robert Z Orlowski  Heinz Ludwig  Thierry Facon  Roman Hajek  Katja Weisel  Vania Hungria  Leonard Minuk  Shibao Feng  Anita Zahlten-Kumeli  Amy S Kimball  Philippe Moreau
Affiliation:1. School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece;2. Heidelberg Medical University, Heidelberg, Germany;3. Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA;4. Royal Prince Alfred Hospital, Camperdown, NSW, Australia;5. National University Cancer Institute, National University Health System, Cancer Science Institute, Singapore;6. National University of Singapore, Singapore;7. Institut Català d''Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;8. MD Anderson Cancer Center, University of Texas, Houston, TX, USA;9. Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria;10. CHRU Lille, Hôpital Claude Huriez, Lille, France;11. University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;12. Universitatsklinikum Tubingen, Tubingen, Germany;13. Santa Casa Medical School, São Paulo, Brazil;14. Cancer Care Manitoba, Winnipeg, MB, Canada;15. Amgen Inc, Thousand Oaks, CA, USA;p. Hematology Department, University of Nantes, Nantes, France
Abstract:
Keywords:Correspondence to: Dr Meletios A Dimopoulos   National and Kapodistrian University of Athens   Alexandra Hospital   Athens 11528   Greece
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号